Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7241497 | 0.83 | DPP4 (0.36) | DPP4 | |
| SCHEMBL1336381 | 0.83 | DPP4 (0.36) | DPP4 | |
| SCHEMBL5516754 | 0.81 | DPP4 (0.35) | DPP4 | |
| Bicarbonate SCHEMBL11385004 | 0.81 | DPP4 (0.35) | DPP4 | |
| SCHEMBL1898374 | 0.81 | DPP4 (0.39) | DPP4 | |
| SCHEMBL25101420 | 0.81 | DPP4 (0.35) | DPP4 | |
| SCHEMBL8049516 | 0.77 | DPP4 (0.34) | DPP4 | |
| SCHEMBL7701354 | 0.74 | MEN1 (0.40) | — | |
| SCHEMBL25101250 | 0.74 | DPP4 (0.33) | DPP4 | |
| SCHEMBL2010918 | 0.72 | DPP4 (0.33) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9272986-B2 | Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150005256-A1 | Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes in Mammalian Systems via an Ecdysone Receptor Complex | INTREXON CORP (US) | 2015-01-01 | — | — | US | disclosed |
| EP-2455375-B1 | Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex | INTREXON CORP (US) | 2014-11-19 | — | — | EP | disclosed |
| US-8748125-B2 | Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2014-06-10 | — | — | US | disclosed |
| EP-2455375-A2 | Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex | Intrexon Corporation (US) | 2012-05-23 | — | — | EP | disclosed |
| US-7851220-B2 | Reduced level of background gene expression; responds to submicromolar concentrations of nonsteroidal ligand | INTREXON CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20080214627-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | HORMANN ROBERT EUGENE | 2008-09-04 | — | — | US | disclosed |
| US-20080194521-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | HORMANN ROBERT EUGENE | 2008-08-14 | — | — | US | disclosed |
| EP-1603860-A4 | DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20080103113-A1 | Reduced level of background gene expression; responds to submicromolar concentrations of nonsteroidal ligand | HORMANN ROBERT E | 2008-05-01 | — | — | US | disclosed |
| US-7304161-B2 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-2-cyano-vinyl)-N'-(3-methoxy-2-methylbenzoyl)-hydrazide | INTREXON CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1603860-A2 | DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene Holdings Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050209283-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-2-cyano-vinyl)-N'-(3-methoxy-2-methylbenzoyl)-hydrazide | ROHM AND HAAS COMPANY | 2005-09-22 | — | — | US | disclosed |
| WO-2004072254-A2 | DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE HOLDINGS, INC (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214627-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | NR5A2, NR5A1, DECR1 | DPP4 3502/4885 |
| US-20080194521-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | NR5A2, NR5A1, DECR1 | DPP4 3502/4885 |
| US-20150005256-A1 | Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes in Mammalian Systems via an Ecdysone Receptor Complex | NR2E3, NR2C2, NR5A2 | DPP4 4594/4885 |
| US-20080103113-A1 | Reduced level of background gene expression; responds to submicromolar concentrations of nonsteroidal ligand | NR5A1, NR0B2, NR0B1 | DPP4 4605/4885 |
| US-20050209283-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-2-cyano-vinyl)-N'-(3-methoxy-2-methylbenzoyl)-hydrazide | NR5A2, NR2C2, NR0B2 | DPP4 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.